Amniotic Fluid Embolism: an Interdisciplinary Challenge

Epidemiology, Diagnosis and Treatment

Werner H. Rath, Stefan Hofer, Inga Sinicina

SUMMARY

Background: Amniotic fluid embolism (AFE) is a life-threatening obstetric complication that arises in 2 to 8 of every 100,000 deliveries. With a mortality of 11% to 44%, it is among the leading direct causes of maternal death. This entity is an interdisciplinary challenge because of its presentation with sudden cardiac arrest without any immediately obvious cause, the lack of specific diagnostic tests, the difficulty of establishing the diagnosis and excluding competing diagnoses, and the complex treatment required, including cardiopulmonary resuscitation.

Methods: We selectively reviewed pertinent literature published from 2000 to May 2013 that was retrieved by a PubMed search.

Results: The identified risk factors for AFE are maternal age 35 and above (odds ratio [OR] 1.86), Cesarean section (OR 12.4), placenta previa (OR 10.5), and multiple pregnancy (OR 8.5). AFE is diagnosed on clinical grounds after the exclusion of other causes of acute cardiovascular decompensation during delivery, such as pulmonary thromboembolism or myocardial infarction. Its main clinical features are severe hypotension, arrhythmia, cardiac arrest, pulmonary and neurological manifestations, and profuse bleeding because of disseminated intravascular coagulation and/or hyperfibrinolysis. Its treatment requires immediate, optimal interdisciplinary cooperation. Low-level evidence favors treating women suffering from AFE by securing the airway, adequate oxygenation, circulatory support, and correction of hemostatic disturbances. The sudden, unexplained death of a pregnant woman necessitates a forensic autopsy. The histological or immunohistochemical demonstration of formed amniotic fluid components in the pulmonary bloodflow establishes the diagnosis of AFE.

Conclusion: AFE has become more common in recent years, for unclear reasons. Rapid diagnosis and immediate interdisciplinary treatment are essential for a good outcome. Establishing evidence-based recommendations for intervention is an important goal for the near future.

► Cite this as:
“cardiovascular collapse,” “disseminated intravascular coagulation,” “maternal death,” “maternal mortality,” and “forensic pathology,” for the period January 2000 to May 2013. Seminal publications dating from before 2000 were also included.

Pathogenesis
The pathogenesis of AFE is not yet fully clear. Amniotic fluid can enter the maternal circulation via endocervical veins, lesions of the uterus, or the site of placental attachment (16).

Although previously proposed explanations of the development of AFE envisaged a purely mechanical obstruction of the pulmonary vessels by amniotic fluid components (17), today humoral and immunological factors are considered to be responsible (18, 19). This is because in addition to insoluble fetal components (e.g. squames) amniotic fluid also contains numerous vasoactive substances (bradykinin, histamine, and others) and procoagulant substances that can lead to endothelial activation and a massive inflammatory reaction (18, 20). These and other immunological and clinical similarities to anaphylactic shock have led to the anaphylactoid reaction hypothesis (anaphylactoid syndrome of pregnancy [11, 17]). This hypothesis is controversial (19). Another pathophysiological mechanism may be complement activation triggering AFE (18, 19). Why some women tolerate the transfer of amniotic fluid or its components with no problems or clinical symptoms and others do not can currently only be the subject of speculation (13); it is also unclear whether allergic diatheses or previous sensitization to specific fetal antigens are disposing factors for AFE (11, 21).

Pathophysiology and clinical manifestation
AFE occurs during labor and delivery/Cesarean section (55% to 76% antenatally) or up to 48 hours postpartum (3, 4, 11). In rare cases, it also occurs during pregnancy following intrauterine surgery (e.g. abortion) or blunt abdominal trauma (6).

<table>
<thead>
<tr>
<th>Incidence of amniotic fluid embolism</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Country</strong></td>
</tr>
<tr>
<td>Australia1</td>
</tr>
<tr>
<td>USA</td>
</tr>
<tr>
<td>Canada</td>
</tr>
<tr>
<td>U.K.</td>
</tr>
<tr>
<td>The Netherlands2</td>
</tr>
</tbody>
</table>

1 Retrospective population-based studies
2 Case-related validation from prospective studies
Modified according to (12), Knight M. et al.: BMC Pregnancy & Childbirth 2012; 12: 7

The main risk factors for AFE are as follows (3): maternal age 35 years or above (odds ratio [OR]: 1.86; 95% confidence interval [95% CI]: 0.99 to 3.48), Cesarean delivery (OR: 12.4; 95% CI: 6.5 to 23.6), placenta previa (OR: 10.5; 95% CI: 0.94 to 117.2), and multiple pregnancy (OR: 8.5; 95% CI: 2.92 to 24.6). Despite discrepancies between studies (4, 5, 22), a recent prospective study proposed that induction of labor increases the risk of AFE by 35% (3). The increasing age of pregnant women (6) and the significantly increased rates of Cesarean sections (7), placentaion disorders (8), and induced labor (22% of all births in Germany in 2012 [9]) may therefore be important influencing factors in the increasing incidence of AFE (9).

Pathophysiologically, the first phase of AFE involves pulmonary vasoconstriction with increased pulmonary resistance and pulmonary hypertension. The cardiac consequences of this are acute right heart failure resulting from pressure overload, with dilatation of the right ventricle and severe tricuspid insufficiency (revealed using transesophageal echocardiography [23, 24]).
Obstetric complications:
- Anaphylactic shock
- Peripartal cardiomyopathy
- Septic shock
- Air embolism

Modified according to (17) and (21)

Differential diagnosis of amniotic fluid embolism
- Pulmonary embolism
- Air embolism
- Acute myocardial infarction
- Septic shock
- Peripartal cardiomyopathy
- Anaphylactic shock
- Anesthesiological complications: high spinal/epidural block, reaction to local anesthetic drugs, aspiration
- Obstetric complications:
  - Placental abruption:
    - Abdominal pain, uterine tetanus, ultrasound evidence of retroplacental hematoma
  - Eclampsia:
    - Tonic-clonic seizures in pre-eclampsia
  - Uterine rupture:
    - Previous Cesarean section, major suprasymphysary pain, sudden cessation of labor
  - Postpartum hemorrhage:
    - e.g. erratic, intermittent bleeding in uterine atony

Modified according to (17) and (21)

Diagnosis

Diagnosis of AFE is based on clinical symptoms after other causes/diagnoses have been excluded. AFE should be considered in every case of sudden maternal cardiovascular collapse and/or maternal death in childbirth with unexplained etiology. There are currently no uniform clinical diagnostic criteria for AFE; the criteria most frequently cited in the current literature are those of the UKOSS (UK Obstetric Surveillance System [3]) and those of Benson (18) (Table 2). The US AFE registry restricts the time of main symptom onset to 30 minutes after birth (11).

To date there are no specific laboratory tests to diagnose AFE.

Evidence of fetal cells in the pulmonary vessels is not a reliable diagnostic criterion and is not pathognomonic for AFE, as fetal cells can be detected in 21% to 100% of pregnant women without AFE (6). Promising diagnostic markers of AFE such as zinc coproporphyrin, sialyl-Tn antigen, tryptase, or C3 and C 4 complement for AFE, as fetal cells can be detected in 21% to 100% of patients (6, 25, 26). In up to 12% of cases the initial symptom of AFE is life-threatening hemorrhage resulting from coagulopathy (27, e10, e11). These symptoms can vary and may manifest in combination with each other and with differing degrees of severity (3).

The second phase of AFE can also include acute left heart failure with consequent pulmonary edema (51% to 100%) (6). Reactive hypovolemia, cardiodepressive humoral factors from the amniotic fluid, and myocardial ischemia play a major role in this (6, 17, 25, e12).

According to the US registry, 56% of women do not survive the first two hours following the acute event (11). In the UKOSS study (3), maternal death occurred at a median of 1 hour, 40 minutes (range: 0 to 23 hours) after manifestation of AFE. Causes of death following survival of the initial phase are sudden cardiac arrest, hemorrhage resulting from coagulopathy or acute respiratory distress syndrome (ARDS), and/or multiple organ failure (6). In 30% to 45% of patients surviving the initial phase, coagulopathy develops with severe bleeding resulting from disseminated intravascular coagulation (DIC), which can occur as early as the first 10 to 30 minutes (within 4 hours in 50% of cases) or up to 9 hours after initial clinical manifestation (11, 26, 28, 29).

The cause of DIC is as yet unclear. Amniotic fluid contains many procoagulant substances (including tissue factor and phosphatidylserine), which can lead directly or indirectly (via cytokines or complement activation) to DIC with consumptive coagulopathy and secondary hyperfibrinolysis via activation of the extrinsic coagulation cascade (18, 21, 30, 31). There is also a controversial hypothesis that coagulopathy may be the result of massive hyperfibrinolysis, as amniotic fluid also contains increased concentrations of urokinase-like plasminogen activator and plasminogen activator 1, among other substances (32, e13, e14). Current coagulation studies using rotational thromboelastometry show signs of hyperfibrinolysis and massive hypofibrinogenemia as early as in the initial phase of AFE (33, e15). Nine cases of uneventful subsequent pregnancy have been reported in women who had AFE in previous pregnancies (6).
**Differential diagnosis**

The symptom mimicry of AFE and the similarities of its main clinical symptoms to those of other diseases (Box) often lead to delays in diagnosis and treatment. Symptom-related clinical pictures can only be defined through careful evaluation of clinical, apparative, and laboratory findings concerning AFE. The most common differential diagnosis is AFE versus pulmonary embolism; the latter differs most markedly from AFE in its typical risk factors, chest pain, rarer initial hypotension, and usually the absence of coagulopathy. Differential diagnoses according to clinical symptoms for AFE versus pulmonary embolism, myocardial infarction, and peripartal cardiomyopathy are shown in Table 3 (e17).

In view of the increasing number of pregnant women with heart diseases, women with cardiovascular risk factors should, wherever possible, receive interdisciplinary counselling prior to a planned pregnancy (e18).

**Treatment**

One possible treatment procedure is shown in Figure 1. Symptom-related acute therapy is based on clinical experience and has little supporting evidence. The highest priority in cases of suspected AFE is to safeguard the airways using endotracheal intubation and early, sufficient oxygenation using an optimized FiO2:PEEP (positive end-expiratory pressure) ratio. Reliable prevention against asphyxia is essential. Depending on hemodynamic status, early use of vasopressors (e.g. noradrenaline, dobutamine) may be indicated in addition to crystalloid-based volume replacement (6, 24). Blood should immediately be taken for laboratory diagnosis including coagulation tests, cross-matching, blood gas analysis, and—if available—rotational thromboelastometry. Rotational thromboelastometry is a point-of-care test to distinguish between hemostasis disorders and to assess their severity. Further measures such as fitting an arterial cannula or central venous catheter should not delay any emergency Cesarean section. In the event of cardiac arrest or life-threatening cardiac arrhythmia, emergency Cesarean section should be performed with resuscitation facilities available, if possible within 3 to 5 minutes (25, 27). This increases the chance of survival of the neonate without neurological disabilities (11) and also improves venous backflow to the right heart by emptying the uterus (21). Also, following successful resuscitation, both mother and child benefit from immediate delivery, and care of the neonate should be optimized by the involvement of a neonatology team. Postpartally, uterotonics should be administered immediately to prevent uterine atony; hysterectomy should be performed promptly in case of treatment-refractory uterine atony or persistent bleeding (13). Differentiated use of catecholamines can be optimized using transesophageal echography (26). Alpha stimulation can if necessary be enhanced using additional inotropy support. Both diagnostically and therapeutically, it is important to monitor cardiac pump function (26).

For subsequent treatment, prompt optimization of coagulation status is the most important measure. In addition to causative therapy, initial administration of tranexamic acid to treat hyperfibrinolysis and the use of fibrinogen concentrate (for fibrinogen levels below 2 g/L) are essential and if possible should be performed using rotational thromboelastometry (33). Replacement of red blood cell concentrates and fresh-frozen plasma

---

**TABLE 3**

<table>
<thead>
<tr>
<th>Differential diagnoses by clinical symptoms</th>
<th>Amniotic fluid embolism</th>
<th>Pulmonary embolism</th>
<th>Myocardial infarction</th>
<th>Peripartal cardiomyopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manifestation/symptoms</td>
<td>During labor/birth</td>
<td>2 to 15 times more common during labor than pregnancy</td>
<td>21% peripartally</td>
<td>Third trimester: approx. 9% to 80% up to 4 months postpartum</td>
</tr>
<tr>
<td>Risk factors</td>
<td>+/nonspecific</td>
<td>+++/specific</td>
<td>+++/specific</td>
<td>+/nonspecific</td>
</tr>
<tr>
<td>Cardiac arrest</td>
<td>++</td>
<td>+ → ++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Chest pain</td>
<td>–</td>
<td>+ → +++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Cardiac arrhythmia</td>
<td>++</td>
<td>+ → +++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>+++</td>
<td>+ → +++</td>
<td>+ → ++</td>
<td>++</td>
</tr>
<tr>
<td>Hypotension</td>
<td>+++</td>
<td>+ → ++</td>
<td>+ → ++</td>
<td>+/–</td>
</tr>
<tr>
<td>Neurological symptoms</td>
<td>++</td>
<td>+ secondary</td>
<td>(+) secondary</td>
<td>(+) secondary</td>
</tr>
<tr>
<td>Coagulopathy</td>
<td>++</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Acute fetal distress</td>
<td>+ → ++</td>
<td>(+) secondary</td>
<td>(+) secondary</td>
<td>No data</td>
</tr>
</tbody>
</table>

- None or rare; +: Occasional; ++: Common; +++: Very common; Table from Rath W.: Fruchtwasserembolie, Lungenembolie (Amniotic Fluid Embolism, Pulmonary Embolism). In: Feige A., Rath W., Schmidt S (eds.): Kreißsaal-Kompendium, Stuttgart, New York, Thieme 2013; 142–9 (e17). Reproduced with the kind permission of Thieme Publishers.

---

**Deutsches Ärzteblatt International | Dtsch Ärztebl Int 2014; 111(8): 126–32**

129
MEDICINE

Even in the event of death from extensive hemorrhage, evidence of AFE can explain what has occurred and can relieve the treating physician of the accusation of violation of the regulations of medical practice (28, 37). For example, evaluation of cause of death information showed that in 30% to 40% of cases of histologically confirmed AFE the clinical conclusion had been hemorrhagic shock, and AFE had not been considered as the indirect cause (38).

As the sudden, unexpected death of a pregnant woman of unknown cause must be classified as “unexplained death,” an autopsy must be requested. Because macropathological findings are nonspecific, cause of death should not be determined without careful histological examination. Detection of formed amniotic fluid components such as usually lamellar, adjacent epidermal squames, meconium components, or lanugo hairs (Figure 2) in the pulmonary bloodflow (FFP) should be performed according to blood loss/severity of bleeding and in line with the risk profile of the patient; care must be taken to avoid volume overload (danger: pulmonary edema) in these pregnant women. FFP should be administered cautiously and preferably while monitoring volume status with TEE (26). The use of recombinant factor VIIa should only be considered if even massive coagulation factor replacement is insufficient to improve hemostasis and stop bleeding (34).

Training programs with an interdisciplinary focus for acute treatment of obstetric emergencies can contribute to improved clinical outcomes (e19, e20). This has begun in individual facilities in Germany.

**Forensic post-mortem evidence of AFE**
The unexpected death of a pregnant woman during childbirth can lead to accusations against a physician if relatives suspect that the cause of death was a treatment error (35, 36). Even in the event of death from extensive hemorrhage, evidence of AFE can explain what has occurred and can relieve the treating physician of the accusation of violation of the regulations of medical practice (28, 37). For example, evaluation of cause of death information showed that in 30% to 40% of cases of histologically confirmed AFE the clinical conclusion had been hemorrhagic shock, and AFE had not been considered as the indirect cause (38).

As the sudden, unexpected death of a pregnant woman of unknown cause must be classified as “unexplained death,” an autopsy must be requested.

Because macropathological findings are nonspecific, cause of death should not be determined without careful histological examination. Detection of formed amniotic fluid components such as usually lamellar, adjacent epidermal squames, meconium components, or lanugo hairs (Figure 2) in the pulmonary bloodflow (FFP) should be performed according to blood loss/severity of bleeding and in line with the risk profile of the patient; care must be taken to avoid volume overload (danger: pulmonary edema) in these pregnant women. FFP should be administered cautiously and preferably while monitoring volume status with TEE (26). The use of recombinant factor VIIa should only be considered if even massive coagulation factor replacement is insufficient to improve hemostasis and stop bleeding (34).

Training programs with an interdisciplinary focus for acute treatment of obstetric emergencies can contribute to improved clinical outcomes (e19, e20). This has begun in individual facilities in Germany.

**Forensic post-mortem evidence of AFE**
The unexpected death of a pregnant woman during childbirth can lead to accusations against a physician if relatives suspect that the cause of death was a treatment error (35, 36). Even in the event of death from extensive hemorrhage, evidence of AFE can explain what has occurred and can relieve the treating physician of the accusation of violation of the regulations of medical practice (28, 37). For example, evaluation of cause of death information showed that in 30% to 40% of cases of histologically confirmed AFE the clinical conclusion had been hemorrhagic shock, and AFE had not been considered as the indirect cause (38).

As the sudden, unexpected death of a pregnant woman of unknown cause must be classified as “unexplained death,” an autopsy must be requested.

Because macropathological findings are nonspecific, cause of death should not be determined without careful histological examination. Detection of formed amniotic fluid components such as usually lamellar, adjacent epidermal squames, meconium components, or lanugo hairs (Figure 2) in the pulmonary bloodflow
MEDICINE

constitutes histological evidence of AFE (3, 28, 36). The fluid component of amniotic fluid cannot be detected histologically. It is important that a representative number of samples (at least one sample from each lung segment, 28) be taken.

Embolic material is found mainly in the pulmonary arterioles and capillaries. Fibrin thrombi, sometimes in connection with amniotic fluid components, are universal and can be detected even after a survival time of two hours or more (Figure 2) (38).

In addition to conventional stains such as hematoxylin eosin as a surveillance stain, Sudan III to show fatty substances, and PAS or alcian blue to visualize mucus, immunohistochemical staining of fetal epithelial cells using cytokeratin is now a standard procedure (28). This allows the severity of AFE to be assessed more precisely. For mild AFE with simultaneous interference by autolysis, epithelial squames in the pulmonary capillaries can only be visualized following immunohistochemical staining with cytokeratin (Figure 3). However, morphologically determined severity of AFE does not correlate with severity of clinical symptoms (38).

An absence of histological evidence of amniotic fluid components in the lung in the first three days following clinical manifestation of AFE and maternal death rules out AFE. In case of an anaphylactoid reaction, the transfer of a small, histomorphologically undetectable amount of amniotic fluid into the maternal circulation may be the cause, but in such cases there would be no histological evidence of DIC. If the mother survives for longer, it should be borne in mind that as yet there is no reliable information on how long amniotic fluid components remain in the maternal circulation (38).

Figure 2: A blood vessel enclosed by lamellar epithelial squames (long dotted arrow) embedded in a fibrin thrombus (two transparent arrows). The lower part of the picture shows a transparent, cylindrical structure corresponding to a lanugo hair (short dotted arrow). Hematoxylin eosin staining: 200x. Survival time: 8 hours

Figure 3: Immunohistochemically marked epithelial squames in pulmonary arterioles (arrows). Cytokeratin, 200x

DEUTSCHE ÄRZTEBLATT INTERNATIONAL | Dtsch Arztebl Int 2014; 111(8): 126–32

Conflict of interest statement
Prof. Rath has received consultancy fees from Ferring and lecture fees from CSL Behring. He has received reimbursement of travel expenses from CSL Behring.

Prof. Hofer has received reimbursement of travel expenses from CSL Behring and lecture fees from CSL Behring, NovoNordis, and Biotest Roche.

Dr. Sinicina declares that no conflict of interest exists.

Manuscript received on 31 July 2013, revised version accepted on 27 November 2013.

Translated from the original German by Caroline Devitt, M.A.
REFERENCES


Corresponding author:
Prof. Dr. med. Werner Rath
Gynecology and Obstetrics
Faculty of Medicine
University Hospital
Wendlingweg 2
52074 Aachen, Germany
wrath@ukaachen.de

For eReferences please refer to:
www.aerzteblatt-international.de/ref0814